Moderna, Inc. (MRNA) 今日盘前股价大涨5.14%，引起了市场的广泛关注。
此次股价上涨主要得益于公司最新公布的财务业绩和研发进展。公司第一季度营收达到3.89亿美元，远超分析师平均预期的2.28亿美元，这主要受益于国际新冠疫苗销量的强劲增长。同时，公司重申了全年营收同比增长10%的目标，表明其正重返销售增长轨道。
此外，公司在AACR会议上披露了其mRNA个性化肿瘤治疗性疫苗EVM16的首次人体数据，结果显示该疫苗具有良好的安全性和初步疗效，为投资者带来了积极的信号。多个候选药物也临近监管批准节点，进一步增强了市场对公司未来发展的信心，共同推动了股价的修复与上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.